Bead Block® and/or all indications may not be available in your territory.
Bead Block is a trademark of Biocompatibles UK Ltd and Bead Block is a registered trademark in China, EU and US.
UFE-Specific Potential Complications:
Bead Block® is manufactured by Biocompatibles UK Ltd;Chapman House;Farnham Business Park;Weydon Lane;Farnham;Surrey;GU9 8QL;UK. Biocompatibles UK Ltd is a BTG International group company. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd. Bead Block is a registered trademark of Biocompatibles UK Ltd.
Please enter your details to download this document.
Bead Block® is an embolic device intended for the purpose of embolising the blood vessels of a variety of hypervascularised tumours (e.g. uterine fibroids) and arteriovenous malformations. Bead Block® is a preformed, deformable microsphere consisting of a biocompatible, acrylamido polyvinyl alcohol macromer.
Bead Block® compressible microspheres are used in embolisation therapy. This is a minimally invasive (non-surgical) procedure performed by an interventional radiologist. By blocking the blood supply to the target area, the tumour or malformation is starved of nutrients and shrinks in size.
Bead Block® microspheres are produced from a biocompatible polyvinyl alcohol hydrogel. The microspheres are tinted blue for easy visualisation and are supplied pre-filled colour coded syringes for added procedural safety and efficiency.
Bead Block® received CE Mark approval in Europe in June 2003 and Bead Block® is most commonly used for the treatment of uterine fibroids and other benign (non-malignant) tumours.
Bead Block® embolic agent offers:
Embolisation of hypervascular renal tumours in combination therapy
Bead Block® embolic agent offers the benefits associated with targeted occlusion of renal vessels and is ideally suited for super-selective arterial embolisation. Recent studies* have demonstrated that super selective embolisation of renal tumours prior to resection or ablation may offer the following benefits:
* Recent Studies: